Free Trial
NASDAQ:IBIO

iBio Q1 2026 Earnings Report

iBio logo
$1.66 -0.06 (-3.22%)
As of 11:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

iBio EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

iBio's Q3 2026 earnings is estimated for Friday, May 15, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 21, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

iBio Earnings Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
iBio, Inc. Common Stock (IBIO)
Ibio (IBIO) Receives a Buy from Chardan Capital
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

View iBio Profile